Investigational drug · Phase 3
MH004
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Vitiligo, Atopic Dermatitis (AD).
Phase 3Last checked: Nov 19, 2026Latest source record: Jun 4, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
0 still active
All registered trials
5
Any phase or sponsor naming "MH004"
First trial start
2023
Jun 10, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "MH004", any sponsor or status.
Conditions studied
As listed on its trial records.
- Vitiligo
- Atopic Dermatitis (AD)
Approved drugs for the same conditions: Atopic dermatitis (eczema) · Immunology and inflammation · Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "MH004" as an intervention, largest first.
- A Phase III Clinical Study to Evaluate the Efficacy and Safety of MH004 Ointment in Non-segmental VitiligoPivotal-lookingRecruiting
Minghui Pharmaceutical (Hangzhou) LtdIndustry
NCT07682506 · 405 participants (planned) · Start Aug 4, 2026 · Primary completion Feb 23, 2028
Drug: MH004 1.0% Ointment; MH004 Placebo Ointment · For: Vitiligo
Sites: Beijing, China
- A Phase 3 Study of MH004 Ointment in Patients With Mild to Moderate Atopic DermatitisPivotal-lookingCompleted
Minghui Pharmaceutical (Hangzhou) LtdIndustry
NCT07185282 · 375 participants · Start Jun 10, 2023 · Primary completion Dec 13, 2024
Drug: MH004 Ointment; Vehicle Ointment · For: Atopic Dermatitis (AD)
Sites: Beijing, China
- MH004 Ointment in Healthy Adult Volunteers and Participants With Mild to Moderate Atopic DermatitisPivotal-lookingCompleted
Minghui Pharmaceutical (Hangzhou) LtdIndustry
NCT07182864 · 160 participants · Start Jan 6, 2022 · Primary completion Sep 8, 2022
Drug: MH004 0.1% Ointment; MH004 0.3% Ointment and 3 more · For: Atopic Dermatitis (AD)
Sites: Shanghai, China
- Phase II Clinical Trial of MH004 Ointment in Patients With Non-segmental VitiligoPivotal-lookingCompleted
Minghui Pharmaceutical (Hangzhou) LtdIndustry
NCT07181187 · 156 participants · Start Mar 26, 2024 · Primary completion Sep 24, 2025
Drug: MH004 Ointment; Vehicle Ointment · For: Vitiligo
Sites: Hangzhou, China
- MH004 Topical Cream in Healthy Adult Volunteers and Participants With Atopic Dermatitis or Rheumatoid ArthritisStatus unknown
Minghui Pharmaceutical Pty LtdIndustry
NCT04815148 · 72 participants (planned) · Start Apr 1, 2021 · Primary completion Mar 31, 2022
Drug: MH004 Ia(0.1%); MH004 Ia(0.3%) and 8 more · For: Atopic Dermatitis; Rheumatoid Arthritis
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Vitiligo
- TEV-53408Phase 32 trials
Teva · Vitiligo, Celiac Disease
- GR2301Phase 22 trials
Genrix (Shanghai) Biopharmaceutical Co., Ltd. · Vitiligo
- LY4005130Phase 22 trials
Eli Lilly · Alopecia Areata, Vitiligo, Non-Segmental Vitiligo (NSV)
- SHR0302BasePhase 22 trials
Jiangsu HengRui Medicine Co., Ltd. · Vitiligo, Non-segmental Vitiligo
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.